Careers Investors News Partners Health Professionals Connect with Us YOUR HEALTH OUR SCIENCE OUR PEOPLE OUR PURPOSE OUR PRODUCTS YOUR HEALTH GET EDUCATED THIS BACK TO SCHOOL SEASON What You Need to Know About Meningococcal Disease. READ HERE NEWS IMPORTANT UPDATE ON EPIPEN® (EPINEPHRINE INJECTION, USP) 0.3 MG AUTO-INJECTORS Extended Expiration Dates for Select Lots of EpiPen® 0.3 mg Auto-Injectors and Its Authorized Generic VIEW THE UPDATE OUR SCIENCE PHENOTYPIC DRUG DISCOVERY MAKES A COMEBACK Phenotypic approaches may also help discover new biological processes and targets. READ MORE YOUR HEALTH ADDRESSING THE UNIQUE HEALTH NEEDS OF AFRICAN AMERICANS The African American Health Engagement Study examines the health attitudes and behaviors of African Americans. READ THE STUDY FINDINGS YOUR HEALTH IS SITTING BEHIND YOUR DESK BAD FOR YOUR HEALTH? If you sit for long periods of time each day working on a computer, you may be at risk for developing physical strain and overuse injuries. LEARN MORE SEARCH PRODUCTS SEARCH PRODUCTS, A–Z OVER-THE-COUNTER PRODUCTS PRESCRIPTION PRODUCTS FIND A TRIAL Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you. Condition, Keyword, or NCT Number Location Advanced Search OUR SCIENCE HOW TO DEAL DANGEROUS PROTEINS A KNOCKOUT BLOW Getting rid of a problematic protein, however, isn’t easy. Since DNA and RNA contain the code for creating individual proteins, scientists long focused on these two nucleic acids as the key to purging proteins. LEARN MORE YOUR HEALTH 5 FACTS ABOUT REAL-WORLD DATA Real-World Data (RWD) can help us further understand the effectiveness, safety and costs associated with a treatment option, potentially offering complementary insights to clinical trial findings. SEE THE 5 FACTS OF RWD LATEST NEWS PFIZER TERMINATES DOMAGROZUMAB (PF-06252616)... Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004... READ MORE YOUR HEALTH Healthy Living Disease & Conditions Managing Your Health OUR SCIENCE Therapeutic Areas Product Pipeline Clinical Trials R&D Platforms Collaboration Research Sites OUR PEOPLE Meet The Experts The Journey Leadership Diverse Perspectives OUR PURPOSE Responsibility Protecting the Environment Positions on Health Policies Transparency Grants Contributions & Partnerships OUR PRODUCTS Product Listing How Drugs are Made Distributors Material Safety Data Sheets Global Product Information Contacts CAREER-SEEKERS INVESTORS NEWS & MEDIA PARTNERS HEALTH PROFESSIONALS BUSINESS TO BUSINESS CHANGE COUNTRY SITEMAP TWITTER FACEBOOK LINKEDIN INSTAGRAM YOUTUBE CONTACT US TERMS OF USE PRIVACY POLICY (NEW) Copyright © 2002-2018 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.